ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$63.22 USD
-0.28 (-0.44%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $63.23 +0.01 (0.02%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.22 USD
-0.28 (-0.44%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $63.23 +0.01 (0.02%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
New Strong Sell Stocks for July 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 16.85% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs
by Zacks Equity Research
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
New Strong Sell Stocks for March 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -8.47% and -6.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
4 Drug/Biotech Outperformers That May Lose Steam in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
New Strong Sell Stocks for December 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Moving Average Crossover Alert: ANI Pharmaceuticals
by Zacks Equity Research
ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ANI Pharmaceuticals (ANIP) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
by Zacks Equity Research
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
by Zacks Equity Research
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
5 Stocks to Consider as New Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
ANI Pharmaceuticals (ANIP) Q2 Earnings Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 11.63% and -2.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes ANI (ANIP) a New Buy Stock
by Zacks Equity Research
ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.
The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI
What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.
American Economy Hits the Gas: 5 Top Gainers
by Tirthankar Chakraborty
The U.S. economy grew 3.2% in the first quarter of 2019, primarily on two typically volatile components - inventories and trade.
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $69.66 in the latest trading session, marking a -0.49% move from the prior day.
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide